Skip to main content

Table 3 Data from Grayscale US, CDUS, CEUS and SE analyses of csPCa and non-csPCa nodules

From: Multiparametric transrectal ultrasound for the diagnosis of peripheral zone prostate cancer and clinically significant prostate cancer: novel scoring systems

Characteristic Non-csPCa csPCa P
Grayscale US    
Echogenicity, n (%)    0.341
 Hypoechoic 62 (54.4) 52 (45.6)  
 Other echo 7 (70.0) 3 (30.0)  
Margin, n (%)    < 0.001
 Clear 22 (95.7) 1 (4.3)  
 Unclear 47 (46.5) 54 (53.5)  
Distribution, n (%)    < 0.001
 Even 38 (77.6) 11 (22.4)  
 Uneven 31 (41.3) 44 (58.7)  
Demarcation of internal and external glands, n (%)    0.031
 Clear 58 (60.4) 38 (39.6)  
 Unclear 11 (39.3) 17 (60.7)  
 Nodule size (mm) 12.99 ± 7.10 16.27 ± 9.24 0.027
CDUS    
Adler grade, n (%)    < 0.001
 Adler II–III 26 (36.1) 46 (63.9)  
 Adler 0–I 43 (82.7) 9 (17.3)  
CEUS    
Enhancement patterns, n (%)    < 0.001
 Synchronous wash-in or out, equal enhancement 43 (93.5) 3 (6.5)  
 Other patterns 26 (33.3) 52 (66.7)  
SE    
SR 45.51 83.82 < 0.001
  1. Other patterns included early wash-in or wash-out and high or low enhancement; late wash-in or wash-out and high or low enhancement
  2. TRUS transrectal ultrasound, US ultrasound, CEUS contrast-enhanced ultrasound, PCa prostate cancer, csPCa clinically significant prostate cancer